- $288.68bn
- $313.21bn
- $54.07bn
REG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in US for early bladder cancer
AnnouncementREG - AstraZeneca PLC - US FDA decision date on camizestrant extended
AnnouncementREG - AstraZeneca PLC - Datroway approved in US for 1L triple-negative BC
AnnouncementREG - AstraZeneca PLC - Camizestrant recommended for breast cancer in EU
AnnouncementREG - AstraZeneca PLC - Enhertu recommended in EU for HER2+ solid tumours
AnnouncementRCS - General Assembly (GA - Business Leaders Primarily Use AI for Simple Tasks
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Enhertu approved in two HER2+ early BC settings
AnnouncementREG - AstraZeneca PLC - Baxfendy approved in the US for hypertension
AnnouncementREG - AstraZeneca PLC - Imfinzi + EV improves EFS & OS in bladder cancer
AnnouncementREG - AstraZeneca PLC - Total Voting Rights and Admission of Shares
AnnouncementREG - AstraZeneca PLC - FDA ODAC vote on camizestrant in breast cancer
AnnouncementREG - AstraZeneca PLC - FDA ODAC recommends Truqap in prostate cancer
AnnouncementREG - AstraZeneca PLC - 1st Quarter Results
AnnouncementREG - AstraZeneca PLC - Breztri approved in the US for asthma
AnnouncementREG - AstraZeneca PLC - Saphnelo self-administration approved in the US
AnnouncementREG - AstraZeneca PLC - Directorate change
AnnouncementREG - AstraZeneca PLC - I CAN PhIII interim analysis met primary endpoint
Announcement